10 months ago
Tisagenlecleucel DLBCL
Tisagenlecleucel DLBCL Diffuse large B-cell lymphoma (DLBCL) is a type of aggressive non-Hodgkin’s lymphoma that affects thousands of people worldwide each year. While traditional treatments ...
10 months ago
10 months ago
Tisagenlecleucel CAR-T: A Breakthrough in Cancer Treatment
Tisagenlecleucel CAR-T: A Breakthrough in Cancer Treatment Tisagenlecleucel, a groundbreaking cellular immunotherapy, has revolutionized the treatment of certain types of cancer. As a CAR T cell th...
10 months ago
Breaking Barriers: Equecabtagene Autoleucel Revives Hope for International RRMM Patients – Multiple Myeloma
Breaking Barriers: Equecabtagene Autoleucel Revives Hope for International RRMM Patients – Multiple Myeloma Multiple Myeloma Relapsed/refractory multiple myeloma (RRMM) presents a significant...
10 months ago
What are the indications for Tisagenlecleucel Approval
What are the indications for Tisagenlecleucel Approval The approval of tisagenlecleucel (Kymriah) by the U.S. Food and Drug Administration (FDA) marks a significant milestone in the field of cancer...
10 months ago
Celebrating Discharge: The Joy of a New Life/ Hope /Multiple myeloma
Celebrating Discharge: The Joy of a New Life/ Hope /Multiple myeloma After a period of treatment, the Singaporean patient Teresa achieved remarkable results with CAR-T therapy at Jiahui Internatio...
10 months ago
庆祝出院：新生的喜悦 /希望之路 /与癌症抗争 /希望 /CART/多发性骨髓瘤
###庆祝出院：新生的喜悦 经过一段时间的治疗，新加坡患者Teresa在上海嘉会国际医院的CAR-T治疗取得了令人振奋的成果。她的病情完全达到了完全缓解（CR），在这一喜讯的见证下，医院为她举行了一场简短而温馨的...
10 months ago
Tecartus Yescarta Difference
Tecartus Yescarta Difference Chimeric Antigen Receptor T-cell (CAR-T) therapies have revolutionized the treatment landscape for certain types of cancer. Tecartus and Yescarta are two such groundbre...
11 months ago
Groundbreaking Results for Chinese CAR-T Therapy: 86% Response Rate of BCMA/GPRC5D Dual-Target Treatment Multiple myeloma
**Groundbreaking Results for Chinese CAR-T Therapy: 86% Response Rate of BCMA/GPRC5D Dual-Target Treatment** Multiple myeloma #MultipleMyeloma #ChineseCART #BCMA #GPRC5D #DualTarget #MM #RRMM Mul...
11 months ago
Tecartus Target – CD19
Tecartus Target – CD19 Tecartus, a groundbreaking CAR-T cell therapy developed by Kite Pharma, a subsidiary of Gilead Sciences, targets CD19, a protein expressed on the surface of certain blo...
11 months ago
Tecartus Price
Tecartus Price Tecartus comes with a substantial price of approximately $373,000 per treatment. Introduction Cancer treatment has come a long way, with advancements in technology and medical resear...
11 months ago
Redefining Hope for High-Risk RRMM Patients Worldwide: A Singaporean Patient`s Journey to China for Groundbreaking CAR-T Therapy
Redefining Hope for High-Risk RRMM Patients Worldwide: A Singaporean Patient`s Journey to China for Groundbreaking CAR-T Therapy Multiple Myeloma #MultipleMyeloma #CAR_Therapy #CancerTreatment #...
11 months ago
Breaking Ground: The First Nectin-4 Targeted ADC Approved in China – Urothelial Carcinoma
**Breaking Ground: The First Nectin-4 Targeted ADC Approved in China** Urothelial Carcinoma #UrothelialCarcinoma #Nectin4 #ADC On August 19, the National Medical Products Administration (NMPA) of...